Table 2 Subgroup analysis of included randomized controlled trials in the systematic review and meta-analysis of comparison of canola oil and olive oil consumption on the serum lipid profile in adults
Variables | Subgroups | No. of trials | P-heterogeneity | I2 (%) | WMD (95% CI) | Pbetween |
|---|---|---|---|---|---|---|
TG | Â | 15 | Â | Â | Â | Â |
| Â | Age | Â | Â | Â | Â | 0.00 |
|  |  < 50 | 7 | 0.00 | 81.8 |  − 36.28 (− 52.20, − 19.46) |  |
|  |  > 50 | 8 | 0.00 | 63.0 |  − 16.81 (− 34.51, 0.88) |  |
| Â | Duration (week) | Â | Â | Â | Â | 0.00 |
|  |  ≤ 60 | 7 | 0.00 | 94.2 |  − 26.54 (− 58.40, 6.19) |  |
|  |  > 60 | 8 | 0.00 | 80.1 |  − 25.66 (− 47.78, − 2.65) |  |
| Â | Dose | Â | Â | Â | Â | 0.00 |
|  |  < 4 | 5 | 0.70 | 0 |  − 14.15 (− 33.62, 5.30) |  |
|  |  ≥ 4 | 9 | 0.00 | 89.8 |  − 34.51 (− 53.09, − 15.92) |  |
| Â | Health status | Â | Â | Â | Â | 0.00 |
|  | Type 2 diabetes | 4 | 0.00 | 78.3 |  − 34.68 (− 73.43, 4.07) |  |
|  | Dyslipidemia | 4 | 0.00 | 88.4 |  − 40.14 (− 58.77, − 21.52) |  |
|  | Others | 7 | 0.14 | 37.5 |  − 12.94 (− 30.52, 4.63) |  |
TC | Â | 16 | Â | Â | Â | Â |
| Â | Age | Â | Â | Â | Â | 0.00 |
|  |  < 50 | 7 | 0.05 | 51.0 |  − 0.85 (− 10.12, 8.42) |  |
|  |  > 50 | 9 | 0.05 | 47.1 | 3.17 (− 4.17, 10.52) |  |
| Â | Duration (week) | Â | Â | Â | Â | 0.00 |
|  |  ≤ 60 | 7 | 0.36 | 8.1 | 7.66 (2.3, 12.99) |  |
|  |  > 60 | 9 | 0.20 | 26.9 |  − 3.83 (− 9.50, 1.83) |  |
| Â | Dose | Â | Â | Â | Â | 0.05 |
|  |  < 4 | 5 | 0.69 | 0 | 5.40 (− 5.12, 15.93) |  |
|  |  ≥ 4 | 10 | 0.02 | 53 |  − 0.94 (− 7.77, 5.89) |  |
| Â | Health status | Â | Â | Â | Â | 0.00 |
| Â | Type 2 diabetes | 4 | 0.69 | 0 | 8.03 (3.49, 12.56) | Â |
|  | Dyslipidemia | 5 | 0.25 | 25.3 | 0.52 (− 7.83, 8.88) |  |
|  | Others | 7 | 0.08 | 45.3 |  − 5.01 (− 15.0, 4.98) |  |
HDL-c | Â | Â | Â | Â | Â | Â |
| Â | Age | Â | Â | Â | Â | 0.00 |
|  |  < 50 | 6 | 0.18 | 33.4 | 1.77 (0.21, 3.33) |  |
|  |  > 50 | 9 | 0 | 88.1 | 3.01 (− 0.82, 6.84) |  |
| Â | Duration (week) | Â | Â | Â | Â | 0.00 |
|  |  ≤ 60 | 6 | 0 | 81.5 | 1.29 (− 2.10, 4.67) |  |
|  |  > 60 | 9 | 0 | 82.6 | 3.58 (0.48, 6.68) |  |
| Â | Dose | Â | Â | Â | Â | 0.00 |
|  |  < 4 | 4 | 0.00 | 75.8 | 6.88 (− 0.80, 3.44) |  |
|  |  ≥ 4 | 10 | 0.02 | 52.5 | 1.91 (0.38, 3.44) |  |
| Â | Health status | Â | Â | Â | Â | 0.00 |
|  | Type 2 diabetes | 4 | 0 | 87 | 3.20 (− 2.68, 9.07) |  |
|  | Dyslipidemia | 5 | 0.11 | 45.8 | 1.64 (− 0.05, 3.33) |  |
|  | Others | 6 | 0 | 84.9 | 3.47 (− 1.99, 8.94) |  |
LDL-c | Â | Â | Â | Â | Â | Â |
| Â | Age | Â | Â | Â | Â | 0.00 |
|  |  < 50 | 7 | 0.01 | 62.1 | 3.42 (− 2.79, 9.63) |  |
|  |  > 50 | 6 | 0.12 | 42.1 | 4.63 (− 2.20, 11.45) |  |
| Â | Duration (week) | Â | Â | Â | Â | 0.00 |
|  |  ≤ 60 | 6 | 0.29 | 17.8 | 9.21 (4.71, 13.70) |  |
|  |  > 60 | 7 | 0.94 | 0 |  − 0.06 (− 1.67, 1.55) |  |
| Â | Dose | Â | Â | Â | Â | 0.02 |
|  |  < 4 | 5 | 0.93 | 0 | 4.30 (− 3.67, 12.27) |  |
|  |  ≥ 4 | 7 | 0 | 70.1 | 2.48 (− 3.78, 8.73) |  |
| Â | Health status | Â | Â | Â | Â | 0.00 |
| Â | Type 2 diabetes | 3 | 0.25 | 27.1 | 9.69 (1.91, 17.47) | Â |
|  | Dyslipidemia | 4 | 0 | 78.4 | 2.65 (− 5.69, 11) |  |
|  | Others | 6 | 0.70 | 0 | 0.67 (− 5.60, 6.93) |  |